BioSpace News Archive

RareCyte ® announces a new dual biomarker liquid biopsy assay for androgen receptor splice variant 7 (ARv7) and the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate both ARv7 and SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer. The ARv

Castlight Health, Inc. (NYSE: CSLT) today announced the addition of Brian Marcotte, former President and CEO, Business Group on Health, as a new strategic advisor.

Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth enabled, virtualized outpatient healthcare treatment company, today announced that it has closed its previously announced underwritten public offering of 1,700,000 shares of its 9.50% Series A Cumulative Perpetual Preferred Stock (the “Series A Preferred Stock“) at $25.00 per share

Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced the appointment of John King as Chief Commercial Officer. Mr. King has more than 20 years of global commercial leadership experience within biotechnology and rare diseases. Mr. King will plan and lead global commercial operations as Vor continues to advance its lead program VOR33 and f

Omega Therapeutics, a company pioneering a new category of genomic medicine through epigenomic programming, today announced new executive hires in a strategic expansion of the Company’s senior management team. Omega has appointed Barbara Chan as Vice President of Finance, and Joe Newman, Ph.D. as Vice President of Biology. This press release features multimedia. View the full release here: https://www.businesswire.c

Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced today it has been awarded a contract by the U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland.

Apnimed, a clinical-stage pharmaceutical company focused on advancing medicines to treat sleep apnea and related disorders, today announced its Scientific Advisory Board (SAB). The SAB will help guide the advancement of the company’s pipeline of small molecule solutions for the treatment of Obstructive Sleep Apnea, or OSA. “OSA represents a significant health problem for more than 25 million Americans, with some es

AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today provided an update on corporate developments. U.S. RECELL® System Sales: July represented the highest monthly sales for RECELL Systems in the United S

CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the pricing of an underwritten public offering of 12,300,000 units at a price to the public of $1.22 per unit. Each unit consists of one share of the Company’s common stock and one warrant to purchase 0.75 of a share of common stock at a per sha

Patients with mild to moderate obesity who underwent bariatric surgery kept their blood pressure under control and required fewer or no medications compared to patients on standard medical therapy, according to a new landmark st